title: Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
abstract: BACKGROUND
  This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention.
  
  
  RESULTS
  A total of 7800 patients were included with an acute coronary syndrome without ST elevation, documented by either elevated cardiac troponin or transient or persistent ST-segment depression. They were randomized to abciximab bolus and 24-hour infusion, abciximab bolus and 48-hour infusion, or matching placebo. The overall 1-year mortality rate was 8.3% (649 patients). One-year mortality was 7.8% in the placebo group and 8.2% in the 24-hour and 9.0% in the 48-hour abciximab infusion group. Compared with placebo, the hazard ratio for the 24-hour infusion of abciximab was 1.1 (95% CI 0.86 to 1.29), and for the 48-hour infusion, it was 1.2 (95% CI 0.95 to 1.41). The lack of benefit of abciximab was observed in every subgroup studied. Patients with negative troponin or elevated C-reactive protein had a higher mortality rate after treatment with abciximab for 48 hours than with placebo: 8.5% versus 5.8% in those with negative troponin (P=0.02), 16.3% versus 12.1% in those with elevated C-reactive protein (P=0.04).
  
  
  CONCLUSIONS
  Compared with placebo, abciximab did not provide any survival benefit at 1 year in patients admitted with an acute coronary syndrome with ST depression and/or elevated troponin who were not scheduled to undergo early coronary revascularization. In subgroups of patients, in particular those with low cardiac troponin or elevated C-reactive protein, abciximab was associated with excess mortality.
authors.affiliation: University Hospital Rotterdam, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: J P
authors.initials: JP
authors.lastname: Ottervanger
authors.forename: P
authors.initials: P
authors.lastname: Armstrong
authors.forename: E S
authors.initials: ES
authors.lastname: Barnathan
authors.forename: E
authors.initials: E
authors.lastname: Boersma
authors.forename: J S
authors.initials: JS
authors.lastname: Cooper
authors.forename: E M
authors.initials: EM
authors.lastname: Ohman
authors.forename: S
authors.initials: S
authors.lastname: James
authors.forename: E
authors.initials: E
authors.lastname: Topol
authors.forename: L
authors.initials: L
authors.lastname: Wallentin
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
mesh_terms: D000077284:Abciximab; D000208:Acute Disease; D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D016019:Survival Analysis; D013577:Syndrome; D016896:Treatment Outcome; D014336:Troponin / Q000097:blood
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014336:Troponin; D002097:C-Reactive Protein; D000077284:Abciximab